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DepressionElevated C-reactive protein (CRP), a non-specific biomarker of systemic bodily inflammation, has been
associated with more pronounced cognitive impairments in adults with psychiatric disorders, particu-
larly in the domains of memory and executive function. Whether this association is present in early life
(i.e., the time at which the cognitive impairments that characterise these disorders become evident), and
is specific to those with emerging psychiatric disorders, has yet to be investigated. To this end, we
examined the association between salivary CRP and cognitive function in children aged 11–14 years
and explored the moderating effect of psychopathology. The study utilised data from an established
longitudinal investigation of children recruited from the community (N = 107) that had purposively
over-sampled individuals experiencing psychopathology (determined using questionnaires). CRP was
measured in saliva samples and participants completed assessments of cognition (memory and executive
function) and psychopathology (internalising and externalising symptoms and psychotic-like experi-
ences). Linear regression models indicated that higher salivary CRP was associated with poorer letter flu-
ency (b = 0.24, p = 0.006) and scores on the inhibition (b = 0.28, p = 0.004) and inhibition/switching
(b = 0.36, p < 0.001) subtests of the colour-word interference test, but not with performance on any
of the memory tasks (working, visual, and verbal memory tasks). Results were largely unchanged after
adjustment for psychopathology and no significant interactions between CRP and psychopathology were
observed on any cognitive measure. Our findings provide preliminary evidence that elevated salivary CRP
is associated with poorer cognitive function in early life, but that this association is not moderated by
concurrent psychopathology. These findings have implications for early intervention strategies that
attempt to ameliorate cognitive deficits associated with emerging psychiatric disorders. Further research
is needed to determine whether salivary CRP levels can be used as a valid marker of peripheral inflam-
mation among healthy adolescents.
 2018 The Authors. Published by Elsevier Inc. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Over the past decade, there have been increased efforts to elu-
cidate the role of inflammatory processes in both the pathogenesis
and symptomology of psychiatric disorders (Haroon et al., 2012).
These efforts have demonstrated that a number of psychiatric dis-
orders, including schizophrenia, bipolar disorder, and depression,
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(CRP), a non-specific biomarker of systemic bodily inflammation
(Fernandes et al., 2016a; Fernandes et al., 2016b; Howren et al.,
2009). Moreover, within these populations, elevated CRP is associ-
ated with poorer cognitive function. Specifically, higher CRP has
been found to correlate with greater cognitive impairments, partic-
ularly in memory and executive function domains, among individ-
uals with schizophrenia (Bulzacka et al., 2016; Dickerson et al.,
2007; Frydecka et al., 2015; Johnsen et al., 2016; Micoulaud-
Franchi et al., 2015); with poorer memory and general cognitive
function in those with bipolar disorder (Dickerson et al., 2013);
and with attention and executive function deficits among individ-
uals with depression (Chang et al., 2012; Krogh et al., 2014). Such
findings lend support to the notion that chronic inflammation may
contribute to the cognitive impairments that typically characterise
these disorders; however, two major questions remain unan-
swered: Firstly, to what extent is the association between CRP
and cognition specific to those with psychiatric disorders? Sec-
ondly, is this association present during early life? The latter is par-
ticularly pertinent given that the cognitive impairments observed
among individuals with these disorders emerge during childhood,
many years before disorder onset (Dickson et al., 2012; Koenen
et al., 2009; Laurens et al., 2015).
Studies examining the relationship between CRP and cognition
among those without psychiatric disorders have typically focused
on distinct sub-populations characterised by cognitive impair-
ments. Much research has focused on healthy older adults
(50 years); both cross-sectional and longitudinal studies indicate
that elevated CRP is associated with poorer cognitive function in
this population (Jenny et al., 2012; Marioni et al., 2009; Noble
et al., 2010; Schram et al., 2007; Teunissen et al., 2003), though
the association is rendered non-significant after adjustment for
sociodemographic factors in some studies (Alley et al., 2008; Dik
et al., 2005; Kao et al., 2011). Whilst a small number of these stud-
ies assessed depression symptoms, none examined the effect of
these symptoms on the relationship between CRP and cognition;
thus, the extent to which this relationship might be explained by
psychiatric morbidity is unknown. Other studies have focused on
populations with specific medical conditions. In cross-sectional
investigations, CRP has been associated with poorer cognitive abil-
ity (again, particularly in the domains of memory and executive
function) in preterm infants (O’Shea et al., 2013; Rose et al.,
2016), infants with congenital heart problems (Li et al., 2014), chil-
dren with obstructive sleep apnoea (Huang et al., 2016), and in
adults experiencing mild traumatic brain injury (Su et al., 2014)
or chronic obstructive pulmonary disease (Crisan et al., 2014).
Inconsistent findings characterise studies examining populations
that are neither exclusively older in age nor characterised by phys-
ical health conditions. A study of adults aged 18–82 years reported
that CRP was not associated with executive function abilities
(Schuur et al., 2010), whilst another large study of 28–91 year olds
observed negative correlations between CRP and slower processing
speed (but not executive function or memory performance) among
African American (but not European American) participants
(Windham et al., 2014). Only two studies, both longitudinal, have
focused on young individuals from the general population; CRP
did not predict memory or executive function in a two-year
follow-up of adolescents (Jonker et al., 2014) or global cognition
in a 13-year follow-up of young adults (Cohen-Manheim et al.,
2015).
Thus, whilst elevated CRP has been associated with greater cog-
nitive impairment in some non-psychiatric samples, the associa-
tion appears to be restricted to populations in which cognitive
impairment is also prevalent (e.g., older adults and those with
physical health conditions). In contrast, a lack of evidence exists
to suggest that CRP predicts later cognitive function in adolescentsand young adults in the general population, which may reflect
follow-up periods exceeding two years that were employed in
these studies. However, the only previous study of adolescents
did not investigate whether the relationship was present among
those experiencing psychopathology (e.g., depression or subclinical
psychotic symptoms). This is important, as opportunities for inter-
vening to improve cognitive deficits associated with psychiatric
disorders (either by psychological or biological means) are likely
to be maximised in early life.
In light of these issues, the current study sought to investigate
associations between inflammation, cognitive impairments, and
emerging psychopathology in childhood, utilising salivary CRP as
a marker of inflammation. Salivary CRP offers a less-invasive alter-
native to blood-based CRP measurement, particularly in child/ado-
lescent populations in which there is often reluctance to provide
blood samples. With the exception of a single study of healthy
adults that failed to find an association between salivary and
serum CRP (Dillon et al., 2010), most previous studies have demon-
strated moderate-to-high correspondence between CRP levels in
serum/plasma and saliva (Byrne et al., 2013; Iyengar et al., 2014;
Ouellet-Morin et al., 2011; Out et al., 2012). The linear relationship
observed between CRP in blood and saliva in these studies implies
that the latter is a valid marker of peripheral inflammation.
Nonetheless, the origin of salivary CRP is currently unclear. It has
been proposed that CRP derived from saliva samples may reflect
systemic CRP (predominately produced by the liver) that has
leaked into gingival crevicular fluid via gingival tissues, though
salivary CRP might also be produced by gingival tissues in response
to periodontal infections (Salimetrics, 2011). By utilising salivary
CRP as a marker of inflammation, the current study provides an
opportunity to determine whether associations observed between
blood-derived CRP and cognition extend to salivary CRP.
Capitalizing on a well-established longitudinal study of children
recruited from the community (Laurens and Cullen, 2016), we
examined the effect of salivary CRP on measures of memory and
executive function in a sample of children aged 11–14 years that
was enriched for children presenting with psychopathology (as
determined using screening questionnaires). We first examined
the predictive effect of salivary CRP on memory and executive
function after adjusting for various methodological and participant
factors that might confound the association. We then explored
interactions between salivary CRP and psychopathology domains
(internalising and externalising symptoms and psychotic-like
experiences) to determine whether any associations between CRP
and cognitive performance differed among children with and with-
out psychopathology. We predicted that, in this sample of adoles-
cents enriched for psychopathology, higher salivary CRP would be
associated with poorer memory and executive function. We also
anticipated that concurrent psychopathology would moderate
the association between CRP and these cognitive functions.2. Materials and methods
2.1. Participants and procedure
The current study uses data from an established longitudinal
investigation of children initially recruited from the general pop-
ulation of South London at age 9–12 years (Laurens and Cullen,
2016; Laurens et al., 2007; Laurens et al., 2011). From the com-
munity sample of 1343 children and caregivers completing
screening, a subset of these participants were selected (N = 123)
to participate in laboratory-based assessments conducted at the
Institute of Psychiatry, Psychology & Neuroscience, King’s College
London, UK. This intensely-studied sample was enriched with
children presenting with psychopathology [developmental delays
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lems (Goodman, 2001); and psychotic-like experiences (Laurens
et al., 2012)] and/or a family history of psychosis [confirmed
using the Family Interview for Genetic Studies (Maxwell,
1992)]; the sample also included unaffected children without
psychopathology or family history of psychosis (44% of those ini-
tially recruited to the study). Children with a neurological condi-
tion (e.g., epilepsy or cerebral palsy), autism, Asperger’s disorder,
or a diagnosed learning disability were not eligible to participate.
Laboratory assessments comprising a variety of biological and
psychosocial measures were completed biennially throughout
adolescence in this cohort. The current study examines data
obtained at a follow-up assessment completed at age 11–
14 years, and includes participants who provided at least one sal-
iva sample at this assessment phase and completed the cognitive
measures described below (N = 107).
At this assessment phase, children and their caregivers pro-
vided written informed assent and consent, respectively, for par-
ticipation. Ethical permission for the study was granted by the
Joint South London and Maudsley and the Institute of Psychiatry
NHS Research Ethics Committee. Caregivers provided information
on family psychiatric history and participant ethnicity [deter-
mined using information obtained using the Family Interview
for Genetic Studies (Maxwell, 1992)] and caregiver occupation
[coded according to the UK National Statistics Socio-economic
Classification (Office for National Statistics, 2010)]. Children com-
pleted the Pubertal Developmental Scale questionnaire
(Carskadon and Acebo, 1993) and provided information on
tobacco and cannabis use via a self-report measure (McVie and
Bradshaw, 2005). Height and weight were collected by the
researcher at the assessment session to compute Body Mass
Index (BMI; kilograms/metres2). The LMS method (Pan and
Cole, 2012) was used to convert raw BMI data into age- and
sex-adjusted standard deviation scores (z scores) using UK
growth reference data (Cole et al., 1998). Participant BMI z scores
were then classified according to clinical centiles as follows: very
underweight (0.4th), low weight (2nd), healthy weight (>2 to
<91st), overweight (91st), obese (98th), and extremely obese
(99.6th). Obese and extremely obese categories were combined
for the purposes of the current study.2.2. Salivary C-reactive protein
2.2.1. Sample collection procedure
As described previously (Cullen et al., 2014), participants
received written instructions for collecting saliva samples at home
using the passive drool procedure recommended for CRP measure-
ment (http://www.salimetrics.com). Participants were asked to
collect six saliva samples throughout the day on two consecutive
days: at awakening, and at 15, 30, and 60 min after awakening,
and at 12:00 h, and 20:00 h. Participants were instructed to wake
before 10:00 h and collect the first sample immediately upon
awakening, to avoid food consumption for 30 min prior to each
sample collection, and to refrain from strenuous exercise. Using a
sampling diary, participants recorded the time of each sample col-
lection, time of awakening, and described their activities during
the day. Participants were also asked to indicate whether they
had experienced any general health problems (i.e., headache, tired-
ness, cold, infection, hay fever, allergies, asthma) or dental prob-
lems (i.e., toothache, mouth ulcer, bleeding gums) during the
past week, including the days of sample collection, via a self-
report checklist. Samples were stored in the participant’s home
freezer until collection, and subsequently frozen at 20 C at the
laboratory for up to five years prior to assay (mean lapse of
time = 1186 days).2.2.2. Salivary CRP assay
Salivary CRP levels were measured using a commercially avail-
able enzyme-linked immunoassay kit from Salimetrics, Suffolk, UK,
following the recommended procedure. Frozen saliva samples
were allowed to thaw at room temperature and centrifuged at
3000 rpm for 15 min to remove mucins. Samples were diluted in
the manufacturer’s buffer (1:10) and assayed in duplicate, using
the Tecan Freedom Evo 100 automated liquid handler. After 2 h
of incubation on a microplate coated with anti-CRP antibodies, in
the presence of diluted enzyme conjugate solution linked to horse-
radish peroxidase, wells were washed four times. A solution of
tetramethylbenzidine was then added and the plate was incubated
in the dark for 30 min with continual mixing. After adding a stop
solution of sulphuric acid and further mixing on a plate rotator
for 3 min, optical density was read on a Beckman Coulter DTX
880 plate reader, with Multimode Detection Software 2.0.012, at
450 nm with correction at 620 nm. SoftMax Pro 4.8 software was
used to calculate the CRP values, following a 4-parameter fit. The
coefficient of variation (CV, calculated as standard devia-
tion * 100/mean) was calculated for each sample to determine
the degree of variation between duplicates.2.2.3. CRP sample availability and effect of methodological factors
Participants were instructed to collect 12 samples over a two-
day period, but participant non-compliance (i.e., failure to collect
all samples) or insufficient saliva available for assay after aliquot-
ing reduced the mean number of saliva samples available for CRP
assay to 5.67 per participant (N = 659; range: 1–12). Rather than
deriving an average CRP value across all time-points (which might
be influenced by the fact that participants were missing data for
different time-points), we used the samples obtained at 12:00 on
Day 1 to examine the association between salivary CRP and cogni-
tion as these were the most prevalent. To establish whether it was
appropriate to use another sample in place of the 12:00 h Day 1
sample (where this sample was unavailable), we performed pre-
liminary analyses on the total dataset (N = 605 after excluding 52
samples with CV values > 20% and 2 samples with extremely high
CRP values) to determine whether CRP values were influenced by
time and day of sampling. In this larger dataset, we also investi-
gated the influence of participant demographic factors on CRP
levels in order to identify potential confounders in the main
analysis.
These preliminary methodological analyses are detailed in the
Supplementary Material. In brief, a mixed effects linear regression
model indicated a significant effect of sampling time on salivary
CRP levels (CRP values for all other time-points significantly lower
relative to the awakening sample, p  0.02) and a significant effect
of day of sampling (CRP levels lower on the second day of collec-
tion, p < 0.001). Neither time of awakening nor length of time in
storage were associated with CRP. With regards to participant fac-
tors, after adjustment for time and day of sampling, those who
reported recent dental problems were characterised by higher
CRP (p = 0.01); however, CRP was not significantly associated with
age, BMI, sex, ethnicity, socioeconomic status, recent health prob-
lems, or a family history of psychosis. Thus, where a 12:00 h Day 1
sample was unavailable, data were replaced with any non-
awakening sample obtained on Day 1 (n = 8), a 12:00 h sample col-
lected on Day 2 (n = 11), or any other Day 2 sample except the
awakening sample (n = 7). Blood CRP values were estimated using
a regression equation (y = 1553.15 x  1413.19; where y = serum
CRP and x = salivary CRP) reported in a previous study examining
the association between salivary and serum CRP in healthy adults
(Ouellet-Morin et al., 2011). Estimated blood CRP values were cal-
culated in order to identify high estimated CRP values [blood
CRP > 10 mg/L (Pearson et al., 2003)] likely to be indicative of acute
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10 mg/L.
2.3. Cognitive assessments
Participants completed a battery of cognitive assessments at the
research session (typically saliva samples were collected by partic-
ipants during the same week, mean lapse of time between cogni-
tive assessment and saliva collection was ±1.4 months). Selected
subtests from the Wide Range Assessment of Memory and Learn-
ing 2nd Edition [WRAML2 (Sheslow and Adams, 2003)] and the
Delis–Kaplan Executive Function System [D-KEFS (Delis et al.,
2001)] were used to assess memory and executive function. Table 1
provides a description of each WRAML2 and D-KEFS subtest
administered. Standardised scores were derived for each subtest
using manual-reported population norms.
2.4. Psychopathology assessments
Children completed the Youth Self-Report (YSR) for school-aged
children (Achenbach and Rescorla, 2001), a widely-used measure
of psychopathology that has been evaluated extensively in child
and adolescent populations and exhibits high reliability and valid-
ity. The YSR incorporates a 112-item checklist of problems occur-
ring during the past six months, each item is scored on a three-
point scale (0 ‘not true’, 1 ‘somewhat true or sometimes true’, or
2 ‘very true or often true’). Item scores can be summed to derive
eight empirically-derived syndrome subscales: (i) anxious/
depressed, (ii) withdrawn/depressed, (iii) somatic complaints, (iv)
social problems, (v) thought problems, (vi) attention problems,
(vii) rule-breaking behaviour, (viii) aggressive behaviour; subscale
scores can then be combined to obtain two overall scores indexing
internalising (subscales i, ii, and iii) and externalising problems
(subscales vii and viii). The YSR provides age- and sex-adjusted
normative data that can be used to categorise internalising and
externalising scale scores as falling within the ‘normal’, ‘border-
line’, or ‘clinical’ ranges. For the purposes of the current study,
we combined the ‘borderline’ and ‘clinical’ groups to create binary
variables (normal vs. borderline/clinical) for both the internalising
and externalising subscales.
Participants additionally completed a nine-item psychotic-like
experiences measure (Laurens et al., 2012; Laurens et al., 2007).Table 1
Memory and executive function measures completed by participants.
Cognitive measure and subtest Normative data Subtest descr
Mean (SD)
Memory: WRAML2 subtests
Number-letter 10 (3) Repeating str
Verbal memory index 100 (15)
Story memory Immediate re
Verbal learning Immediate fr
Visual memory index 100 (15)
Design memory Drawing five
Picture memory Identifying d
Verbal working memory 10 (3) Immediate re
Executive function: D-KEFS subtests
Verbal fluency test
Letter fluency 10 (3) Generating w
Category fluency 10 (3) Generating it
Colour-word interference test
Inhibition 10 (3) Naming the i
Inhibition/switching 10 (3) Alternating b
whilst ignori
Towers test
Total achievement score 10 (3) Building tow
Note. WRAML2: Wide Range Assessment of Memory and Learning 2nd edition; D-KEFS:This measure included a range of hallucination- and delusion-like
experiences, each rated on a three-point scale (0 ‘not true’, 1
‘somewhat true’, or 2 ‘certainly true’). A binary variable was
derived indicating the presence of at least one experience rated
somewhat or certainly true.
2.5. Statistical analyses
Analyses were conducted using Stata version 12 (StataCorp,
2011). Cognitive scores, but not salivary CRP scores, were approxi-
mately normally distributed in the current sample (N = 107).
Applying a square root transformation to the salivary CRP variable
improved the skewness but not the kurtosis (values 0.47 and 4.20,
respectively), therefore all regression analyses using the trans-
formed CRP variable were performed with robust standard errors.
Linear regression analyses were conducted to examine the associa-
tion between CRP (independent variable: IV) and each cognitive
subtest examined (dependent variable: DV); as noted above, all
regression analyses were adjusted for sampling day and recent den-
tal problems owing to the association of these variables with sali-
vary CRP (see Supplementary Material). Standardised beta values
(b) are presented for ease of comparison across cognitive subtests.
In supplementary analyses, the association between each psy-
chopathology variable (IV) and CRP (DV) was examined (Supple-
mentary Material). We then repeated all analyses examining the
effect of CRP on cognition with current psychopathology included
as additional covariates; in the final step, interactions between each
psychopathology variable and CRP were included in each model.
3. Results
3.1. Sample characteristics
Demographic characteristics of the sample are displayed in
Table 2. The mean age of participants at the time of CRP collection
was 13.2 years and approximately half (48.1%) were male. Consis-
tent with the ethnic diversity known to characterise the population
from which participants were sampled, one third were of white
British ethnicity. Just over one quarter (27.1%) had a first- or
second-degree relative with a psychotic disorder (schizophrenia,
schizoaffective disorder, or bipolar disorder). With regards to cur-
rent psychopathology, 17.1% and 10.5% of participants scored iniption
ings of numbers and letters presented orally
call of two short stories presented orally
ee recall of a list of words presented orally
visually-presented geometric designs
ifferences between four similar pairs of pictures
call of word lists by category (animal vs. non-animal)
ords beginning with F, A, and S within 60 s
ems from categories (animals and boys names) within 60 s
nk colour of colour-words presented in contrasting coloured ink
etween the Inhibition condition described above and naming the colour-word
ng ink colour
ers using one to five disks in the fewest possible moves
Delis–Kaplan Executive Function System.
Table 2
Sample demographics.
Total sample
(N = 107)
Age (years); mean (SD) 13.2 (1.1)
Male sex; n (%) 51 (48.1)
BMI (kilograms/metres2); mean (SD) 19.8 (3.2)
BMI categories
Healthy weight 84 (80.8)
Overweight 15 (14.4)
Obese 5 (4.8)
Ethnicity; n (%)
White British 35 (32.7)
White other 28 (26.2)
Black African or Caribbean 12 (11.2)
Other 32 (29.9)
Socioeconomic status based on parental occupation; n (%)
Higher managerial, administrative, and professional 67 (62.6)
Intermediate 26 (24.3)
Routine and manual 14 (13.1)
Tobacco use; n (%) 2 (1.9)
Cannabis use; n (%) 3 (2.8)
Family history of psychosis; n (%)b 29 (27.1)
Salivary CRP (raw) pg/ml; mean (SD) 2027.6 (1070.2)
Salivary CRP (SQRT transformed) pg/ml; mean (SD) 43.6 (11.3)
YSR Internalising ‘borderline/clinical’ range; n (%) c 18 (17.1)
YSR Externalising ‘borderline/clinical’ range; n (%) d 11 (10.5)
Reported  1 ‘somewhat true’ psychotic-like experience,
n (%) e
46 (43.0)
WRAML2: Number letter; mean (SD) 12.2 (3.2)
WRAML2: Verbal memory; mean (SD) 106.7 (12.7)
WRAML2: Visual memory; mean (SD) 90.7 (13.2)
WRAML2: Verbal working memory; mean (SD) 10.2 (2.3)
D-KEFS: Letter fluency; mean (SD) 10.6 (2.7)
D-KEFS: Category fluency; mean (SD) 12.5 (3.1)
D-KEFS: CW Inhibition; mean (SD) 11.1 (2.3)
D-KEFS: CW Inhibition/switching; mean (SD) 10.8 (2.3)
D-KEFS: Towers test; mean (SD) 11.4 (1.9)
Note. SD, standard deviation; BMI: Body Mass Index; CRP: C-reactive protein; SQRT:
square root; pg/ml: picograms per millilitre; YSR: Youth Self-Report; WRAML2:
Wide Range Assessment of Memory and Learning 2nd edition; D-KEFS: Delis–
Kaplan Executive Function System; CW: colour-word interference test. aIncludes
schizophrenia and schizoaffective disorder. bYSR Internalising: ‘borderline’ (n = 6);
‘clinical’ (n = 12); cYSR Externalising: ‘borderline’ (n = 4); ‘clinical’ (n = 7). eNo. of
somewhat or certainly-true PLEs reported: 1 (n = 18); 2 (n = 15); 3 (n = 4); 4 (n = 5);
5 (n = 2); 6 (n = 1); 8 (n = 1). Missing data: BMI (n = 3); WRAML2 number letter
(n = 3) WRAML2 verbal and visual memory indices (n = 1); WRAML2 verbal work-
ing memory (n = 1); D-KEFS letter and category fluency (n = 2); D-KEFS CW inhi-
bition and inhibition/switching (n = 3); D-KEFS tower test (n = 2); YSR internalising
(n = 2); YSR externalising (n = 2).
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ising scales, respectively, and 43.0% of the sample reported at least
one somewhat/certainly true psychotic-like experience.3.2. Predictive effect of CRP on cognitive performance
Table 3 presents the results of linear regression analyses exam-
ining the association between salivary CRP and cognitive perfor-
mance after adjustment for methodological and demographic
factors (sampling day and recent dental problems). Analyses indi-
cated a significant association between CRP and several measures
of executive functioning; specifically, higher salivary CRP was asso-
ciated with lower scores on the letter fluency subtest of the verbal
fluency test (b = 0.24, p = 0.006), with a statistical trend observed
also for lower category fluency subtest scores (b = 0.17, p = 0.08).
Additionally, higher CRP levels were associated with significantly
poorer performance on both the inhibition (b = 0.28, p = 0.004)
and inhibition/switching (b = 0.36, p < 0.001) subtests of the
colour-word interference test. In contrast, CRP was not signifi-
cantly associated with scores on the D-KEFS towers test or perfor-
mance on any of the WRAML2 memory measures.3.3. Association between current psychopathology and CRP
Linear regression analyses, adjusted for sample day and recent
dental problems, indicated that internalising problems, externalis-
ing problems, and psychotic-like experiences were not signifi-
cantly associated with salivary CRP (p > 0.05, Supplementary
Material).
3.4. Effect of current psychopathology on the association between CRP
and cognition
Analyses were next performed to examine the association
between salivary CRP and cognitive scores after additionally adjust-
ing for psychopathology variables. As shown in Table 3, the pattern
of results was largely unchanged; salivary CRP remained signifi-
cantly associated with scores on the D-KEFS letter fluency subtest
of the verbal fluency test and the D-KEFS inhibition and inhibition-
switching subtests of the colour-word interference test (p < 0.01
for all). The association between CRP level and D-KEFS category flu-
ency subtest scores, however, reduced in significance although the
standardised beta value did not change (b = 0.17, p = 0.10).
3.5. Moderating effects of psychopathology
As a final step, interaction terms between CRP and each of the
three psychopathology domains (internalising and externalising
symptoms and psychotic-like experiences) were additionally
included in each model; however, as no significant interaction
effects were observed (see Table 3), these were dropped from the
final models.
3.6. Consideration of additional factors
All analyses were repeated after including lapse of time
between cognitive assessment and salivary CRP sampling, with
no change to the overall pattern of results (i.e., all previously
reported statistically significant results remained significant). Only
one participant in the sample may have recently used psychotropic
medication (stimulant medication had been prescribed to this par-
ticipant at the current follow-up assessment, which may have been
used in the days preceding saliva collection); however, none of the
participants had taken medication on either of the saliva collection
days. CRP data for this participant were not outliers within the cur-
rent sample and the results of the main analyses examining the
relationship between salivary CRP and cognition were unchanged
after excluding this participant.4. Discussion
In this sample of children aged 11–14 years, enriched for those
presenting with psychopathology, we examined the association
between salivary CRP and cognitive performance, and, for the first
time, the extent to which this relationship was modified by con-
current psychopathology. Consistent with previous studies exam-
ining CRP from blood samples, we showed that higher salivary
CRP levels are associated with poorer performance on several exec-
utive functioning measures, thereby demonstrating the potential
utility of salivary CRP in populations where there is reluctance to
provide blood samples. However, salivary CRP was not associated
with scores on memory subtests. The pattern of findings was
unchanged after adjusting for current psychopathology (internalis-
ing and externalising symptoms and psychotic-like experiences)
and we observed no significant interactions between salivary CRP
and these psychopathology domains. Thus, the current findings
provide no evidence to suggest that the association of salivary
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among, adolescents characterised by emerging psychopathology.
Our findings should be interpreted cautiously owing to our use
of salivary CRP alone as a measure of systemic inflammation. Stud-
ies examining the concordance between salivary CRP and blood-
derived CRP values have yielded mixed findings; whilst most stud-
ies have shown moderate-to-high correlations (Byrne et al., 2013;
Iyengar et al., 2014; Ouellet-Morin et al., 2011; Out et al., 2012)
others have not (Dillon et al., 2010). It is important to note that
only one of these studies examined adolescents (Byrne et al.,
2013). As that study observed significant associations between
salivary and serum CRP among adolescents with high serum CRP,
but not those with low serum CRP, the extent to which salivary
CRP is a valid marker of systemic inflammation in our sample of
relatively healthy adolescents is unclear. In light of these findings,
we do not advocate that researchers measure CRP in saliva only,
but rather, when possible, measure both salivary and blood CRP
levels in order to further test the extent to which salivary CRP rep-
resents a valid, non-invasive biomarker of systemic inflammation.
Our extended analyses indicated that salivary CRP levels were
not significantly elevated among children classified as obese (see
Supplementary Material), a finding that has been observed in pre-
vious studies of children aged 7–12 years (Goodson et al., 2014;
Naidoo et al., 2012). In both previous studies, participant BMI cat-
egories were derived from US growth charts (Ogden et al., 2002)
which differ from the British 1990 categories utilised in the current
study (Lang et al., 2011), potentially contributing to our divergent
finding. Alternatively, the fact that only a small proportion of our
sample were classified as obese (4.8%) may have limited our ability
to detect significant elevations in CRP in this group. Our use of sali-
vary CRP also meant that we were unable to definitively identify
participants with high CRP values, indicative of acute systemic
infection or illness. Whilst we attempted to estimate blood CRP
levels using previously-published data (Ouellet-Morin et al.,
2011), further studies are needed to confirm the validity of this
approach. Nonetheless, we observed robust associations between
salivary CRP and cognitive function that mirrored those reported
in studies utilising blood-derived CRP.
The current study is the first to demonstrate that CRP measured
in saliva is predictive of poorer performance on several measures
of executive function. Our findings obtained in this sample of chil-
dren enriched for psychopathology are consistent with previous
studies in which significant associations between blood-derived
CRP levels and executive function have been observed among indi-
viduals with psychiatric disorders (Dickerson et al., 2013; Krogh
et al., 2014; Micoulaud-Franchi et al., 2015), older adults
(Marioni et al., 2009; Schram et al., 2007), and children with
obstructive sleep apnoea (Huang et al., 2016). Contrary to our
hypotheses, salivary CRP levels were unrelated to performance
on any of the memory measures examined in the current study.
This is surprising given the wealth of studies that have previously
found CRP to be associated with memory performance in both psy-
chiatric samples and older adults (Bulzacka et al., 2016; Dickerson
et al., 2013; Frydecka et al., 2015; Johnsen et al., 2016; Marioni
et al., 2009; Noble et al., 2010; Teunissen et al., 2003). It is possible
that, among healthy adolescents, elevated CRP is specifically
related to executive function but not memory performance. As dis-
cussed in detail below, the specific executive function domains
examined in the current study might be served by brain regions
which are particularly sensitive to the effects of elevated CRP dur-
ing adolescence. Alternatively, it may be that our cognitive mea-
sures did not capture the specific impairments in memory that
might be associated with elevations in CRP.
Our finding that psychopathology had neither a confounding
nor moderating effect on the association of CRP and cognitive per-
formance is in contrast to our hypotheses. Given that CRP has been
A.E. Cullen et al. / Brain, Behavior, and Immunity 66 (2017) 221–229 227associated consistently with cognition in samples of individuals
with psychiatric disorders (schizophrenia, bipolar disorder, and
depression), but not in samples of healthy individuals, we expected
that the relationship between CRP and cognition would be more
prominent among those with concurrent psychopathology. We
found no evidence to support this. This may be due to the fact that
the indices of psychopathology that we examined in the current
study (i.e., scores in the borderline/clinical range of the YSR and
the presence of at least one somewhat/certainly true psychotic-
like experience) were of insufficient severity to moderate the effect
of CRP on cognitive function. It is possible that clinically-
determined psychiatric disorders may show interaction effects
with CRP. Alternatively, CRP may be predictive of poor cognitive
performance irrespective of concurrent psychopathology. Given
that this appears to be the first study to examine potential interac-
tion effects between CRP and psychopathology domains, it will be
important to conduct similar analyses in larger samples to more
definitively address these questions.
To our knowledge, only one previous study has examined the
association of CRP and cognitive function in adolescents recruited
from the general population (Jonker et al., 2014). In contrast to
the current findings, this large, longitudinal study of 1084 adoles-
cents observed that CRP was not associated with memory or exec-
utive function at a two-year follow-up. There are several possible
explanations for why our findings do not concur with this study.
Firstly, our analyses were cross-sectional; it is possible that within
adolescent samples (where cognitive function might be expected
to change over time) CRP might be associated with concurrent cog-
nitive performance only. Secondly, the study by Jonker and col-
leagues included only a single measure of executive functioning
(the self-ordered pointing task, (Ross et al., 2007)), which may be
less sensitive to the effects of inflammation. Finally, our sample
was enriched for children presenting with psychopathology; we
might therefore expect some individuals within our sample to be
characterised by poorer cognitive performance relative to the gen-
eral population. However, with the exception of scores on the
WRAML2 visual memory index, mean scores on all cognitive sub-
tests were higher than the manual-reported means based on nor-
mative data (see Table 1). Moreover, as noted above, we found
no evidence to suggest that psychopathology moderated the rela-
tionship between CRP and cognitive performance.
4.1. Potential mechanisms
Our findings provide tentative support for the suggestion that
peripheral inflammation, as estimated via salivary CRP, might con-
tribute to impairments in cognitive function. However, the mecha-
nisms underlying this process have not been elucidated fully.
Whilst it was previously thought that the brain was protected from
the effects of systemic inflammation and immune responses, this
has been revised in light of recent evidence that the brain responds
to peripheral inflammation and that CRP has neurotoxic properties
(for a review see (Warnberg et al., 2009)). In the current study, we
observed that salivary CRP was specifically associated with perfor-
mance on the letter fluency task and the colour-word interference
test (similar to the Stroop test; (Stroop, 1935)). Meta-analyses of
functionalMRI studies indicate that these tests are related to partic-
ular brain regions, largely those located in the frontal lobe. Specifi-
cally, letter fluency performance is associated with activation of the
left inferior/middle frontal gyrus, bilateral anterior cingulate, and
the right insula/frontal lobe (Wagner et al., 2014), whilst the ante-
rior cingulate and inferior frontal junction (bridging the inferior
frontal sulcus and the inferior precentral sulcus) as well as other
frontal regions have been implicated in the colour-word Stroop test
(Cieslik et al., 2015; Derrfuss et al., 2005). Longitudinal MRI studies
indicate that the brain continues to grow and reorganise through-out adolescence and that the frontal brain regions are among the
last to fullymature (Johnson et al., 2009). Thus, one potential reason
for why we observed significant associations between salivary CRP
and these specific executive functioning measures in this adoles-
cent sample is that the frontal brain regions that subserve these
cognitive abilities are under-developed and therefore particularly
vulnerable to the effects of CRP. However, it is important to note
that in this cross-sectional study it is not possible to determine that
CRP has a causal effect on cognitive impairment. Moreover, in the
absence of blood-derived CRP data, our findings cannot provide
direct evidence of a relationship between systemic inflammation
and cognition among relatively healthy adolescents; thus, the
mechanisms we propose here should be treated as speculative.
Given that none of the participants exhibited high CRP values
indicative of acute infection (see Section 2.2.3), one important
question relates to how the association between ‘moderately ele-
vated’ salivary CRP and executive function should be interpreted.
Our finding that salivary CRP was not related to recent health prob-
lems is consistent with previous studies of healthy adults (Ouellet-
Morin et al., 2011; Out et al., 2012) and implies that the association
is not driven by poor general health. Accumulated evidence indi-
cates that elevated CRP in later life is predicted by a range of prena-
tal exposures [e.g., maternal depression and social adversity (Plant
et al., 2016; Slopen et al., 2015)], and childhood adversities [e.g.,
trauma/maltreatment, bullying, and economic/social disadvantage
(Baumeister et al., 2016; Copeland et al., 2014; Slopen et al.,
2015)]. Thus, the associations that we observed in this sample of
children enriched for psychopathologymight reflect a general effect
of childhood adversity on both inflammation and cognitive func-
tioning. Further research, utilising larger samples, is needed to
explore the potentially mediating role of childhood adversity.
4.2. Implications
Our findings lend further credence to the notion that the rela-
tionships between CRP and cognitive impairments observed
among individuals with psychiatric disorder, older adults, and indi-
viduals with underlying physical health problems are not merely
epiphenomena. Whilst the associations observed in these popula-
tions may be confounded by illness chronicity, medication effects,
or neuroanatomical changes, such confounders are minimised in
this sample of adolescents enriched for psychopathology. More-
over, our findings show that these associations are present in early
life before the onset of severe psychiatric disorders. Collectively,
our findings and those previous studies, tentatively suggest that
novel treatments targeting systemic inflammation might lead to
a reduction in persistent cognitive symptoms among psychiatric
patients. Such treatment developments are welcomed given that
the cognitive features that characterise psychiatric disorders often
show only small-to-moderate responses to pharmacological treat-
ments (Mishara and Goldberg, 2004; Rosenblat et al., 2015). One
such candidate might be statin therapy, administration of which
has been found to attenuate circulating CRP concentration
(Albert et al., 2001) and has also been associated with a reduction
in cognitive symptoms among individuals with Alzheimer’s disease
(Sparks et al., 2006). It remains a question for future research
whether statin therapy might induce significant improvement in
cognitive symptoms among those already diagnosed with psychi-
atric disorder, possibly by reducing circulating CRP concentration.
4.3. Limitations
Several limitations must be noted. Firstly, the current study is
limited by the relatively small sample size, which may have
reduced our ability to detect significant associations. Secondly, in
this small sample, ‘psychopathology’ was defined as a score in
228 A.E. Cullen et al. / Brain, Behavior, and Immunity 66 (2017) 221–229the borderline/clinical range of the YSR and at least one somewhat/
certainly true psychotic-like experience. Thus, our ability to detect
significant interaction effects between CRP and psychopathology
may have been limited by the fact that we used a leniently-
defined threshold for psychopathology. A third limitation relates
to the fact that we examined only CRP levels in saliva. A previous
study using blood-derived markers observed that poor cognitive
performance was associated with elevated inflammatory cytoki-
nes, but not CRP, among patients with depression (Goldsmith
et al., 2016). Our failure to find significant associations between
elevated CRP and memory performance, or any moderating effect
of psychopathology, might be because CRP (either in saliva or
blood) is not a sufficiently sensitive measure of inflammation.
Finally, whilst saliva samples were typically obtained within one
week of cognitive assessments, this was not always possible (mean
lapse of time 1.4 months). As CRP levels may change over time, this
delay may have reduced our ability to find significant associations
between CRP and cognitive function.
4.4. Conclusions
Consistent with studies examining serum/plasma CRP among
patients with psychiatric disorders, older adults, and individuals
with physical health conditions, we have demonstrated that ele-
vated salivary CRP is associated with poorer performance on mea-
sures of executive function in this sample of children aged 11–
14 years that is enriched for those presenting with psychopathol-
ogy. In contrast to expectations, psychopathology did not appear
to modify the effect of CRP on cognition. Our findings obtained in
this sample of relatively healthy adolescents, where confounding
factors such as medication use, illness chronicity, and neu-
roanatomical changes are minimised, provide further evidence to
suggest that the association between CRP and cognitive function
is not merely an epiphenomenon, though the absence of blood-
derived CRP data prevents us from drawing definitive conclusions
regarding the role of peripheral inflammation in cognitive function.
Nevertheless, the robust associations that we observed in this sam-
ple of adolescents between salivary CRP and executive function,
which withstood adjustment for a range of factors, provide exciting
prospects for intervention strategies aimed at reducing cognitive
impairments in vulnerable populations.
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